JP2018521121A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521121A5 JP2018521121A5 JP2018516398A JP2018516398A JP2018521121A5 JP 2018521121 A5 JP2018521121 A5 JP 2018521121A5 JP 2018516398 A JP2018516398 A JP 2018516398A JP 2018516398 A JP2018516398 A JP 2018516398A JP 2018521121 A5 JP2018521121 A5 JP 2018521121A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- group
- xrpd
- diffractometer
- radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims 20
- 239000013078 crystal Substances 0.000 claims 10
- 230000005855 radiation Effects 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000002245 particle Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 239000004381 Choline salt Substances 0.000 claims 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 3
- 235000019417 choline salt Nutrition 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 150000003248 quinolines Chemical class 0.000 claims 3
- 108010059108 CD18 Antigens Proteins 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 230000008719 thickening Effects 0.000 claims 1
- 208000037816 tissue injury Diseases 0.000 claims 1
- AEZGRQSLKVNPCI-UNOMPAQXSA-N OC(c(cc1)ccc1-c1ccc(/C=C(/C(N2Cc3ccccc3)=O)\SC2=S)[o]1)=O Chemical compound OC(c(cc1)ccc1-c1ccc(/C=C(/C(N2Cc3ccccc3)=O)\SC2=S)[o]1)=O AEZGRQSLKVNPCI-UNOMPAQXSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175066P | 2015-06-12 | 2015-06-12 | |
| US62/175,066 | 2015-06-12 | ||
| US201662275655P | 2016-01-06 | 2016-01-06 | |
| US62/275,655 | 2016-01-06 | ||
| PCT/US2016/037067 WO2016201356A1 (en) | 2015-06-12 | 2016-06-10 | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018521121A JP2018521121A (ja) | 2018-08-02 |
| JP2018521121A5 true JP2018521121A5 (enExample) | 2019-07-18 |
Family
ID=57504544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516398A Pending JP2018521121A (ja) | 2015-06-12 | 2016-06-10 | （ｚ）−４−（５−（（３−ベンジル−４−オキソ−２−チオキソチアゾリジン−５−イリデン）メチル）フラン−２−イル）安息香酸の固体形状 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10723726B2 (enExample) |
| EP (1) | EP3307722B1 (enExample) |
| JP (1) | JP2018521121A (enExample) |
| KR (1) | KR102663856B1 (enExample) |
| CN (1) | CN107848991B (enExample) |
| AU (2) | AU2016275125A1 (enExample) |
| BR (2) | BR112017026406A2 (enExample) |
| CA (2) | CA3221219A1 (enExample) |
| ES (1) | ES2896674T3 (enExample) |
| IL (1) | IL256237B (enExample) |
| SG (1) | SG10201911442XA (enExample) |
| WO (1) | WO2016201356A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3307722B1 (en) | 2015-06-12 | 2021-08-04 | GB006, Inc. | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
| US20200123146A1 (en) * | 2016-12-29 | 2020-04-23 | Gb006, Inc. | Heterocyclic integrin agonists |
| DK3601265T3 (da) * | 2017-03-30 | 2023-09-18 | Merck Patent Gmbh | Fast form af (s)-[2-chlor-4-fluor-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol |
| TW202024061A (zh) | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| CA3103522C (en) | 2018-07-16 | 2023-11-21 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
| EP3889136B1 (en) | 2018-11-28 | 2024-12-18 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor |
| WO2020236667A1 (en) * | 2019-05-17 | 2020-11-26 | Gb006, Inc. | Methods of treating cancer |
| WO2021061665A1 (en) * | 2019-09-23 | 2021-04-01 | Gb006, Inc. | Integrin agonist prodrugs |
| WO2021096988A1 (en) | 2019-11-12 | 2021-05-20 | Gb006, Inc. | Crystalline salt forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
| WO2023039170A1 (en) * | 2021-09-09 | 2023-03-16 | Musc Foundation For Research Development | Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy |
| WO2024049275A1 (en) * | 2022-09-02 | 2024-03-07 | Rexpharmtech Co., Ltd | Novel benfotiamine choline salt |
| WO2024081449A1 (en) * | 2022-10-14 | 2024-04-18 | Rush University Medical Center | Cd11b agonists for treatment of autoimmune disease |
| CN121197154B (zh) * | 2025-11-13 | 2026-06-23 | 首都医科大学附属北京天坛医院 | Mac-1激动剂在制备治疗和/或缓解脑出血药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040002526A1 (en) | 2002-04-03 | 2004-01-01 | Cell Therapeutics, Inc. | Phospholipase D inhibitors and uses thereof |
| EP1654380A4 (en) | 2003-08-14 | 2009-09-09 | Insight Biopharmaceuticals Ltd | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF |
| TW200526638A (en) * | 2003-10-22 | 2005-08-16 | Smithkline Beecham Corp | 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline |
| FI20041129A0 (fi) | 2004-08-30 | 2004-08-30 | Ctt Cancer Targeting Tech Oy | Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi |
| US7718680B2 (en) * | 2004-09-23 | 2010-05-18 | Burnham Institute For Medical Research | Inhibition of lethal factor protease activity from anthrax toxin |
| ITMI20042475A1 (it) * | 2004-12-23 | 2005-03-23 | Cell Therapeutics Europe Srl | Uso di derivati tiazolidinonici come agenti terapeutici |
| WO2008005651A2 (en) * | 2006-06-08 | 2008-01-10 | Decode Chemistry, Inc. | Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis |
| WO2008082537A2 (en) | 2006-12-19 | 2008-07-10 | The General Hospital Corporation | Compounds for modulating integrin cd11b/cd18 |
| WO2008091532A1 (en) * | 2007-01-19 | 2008-07-31 | Panacos Pharmaceuticals, Inc. | Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof |
| US9023876B2 (en) * | 2010-07-08 | 2015-05-05 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
| CN103159695B (zh) * | 2011-12-08 | 2015-08-12 | 首都师范大学 | 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途 |
| CA2882853C (en) | 2012-04-20 | 2021-11-23 | Vineet Gupta | Compounds and methods for regulating integrins |
| EP3307722B1 (en) | 2015-06-12 | 2021-08-04 | GB006, Inc. | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
-
2016
- 2016-06-10 EP EP16808465.5A patent/EP3307722B1/en active Active
- 2016-06-10 BR BR112017026406-4A patent/BR112017026406A2/pt not_active Application Discontinuation
- 2016-06-10 KR KR1020177037752A patent/KR102663856B1/ko active Active
- 2016-06-10 CA CA3221219A patent/CA3221219A1/en active Pending
- 2016-06-10 BR BR122023025347-7A patent/BR122023025347A2/pt not_active Application Discontinuation
- 2016-06-10 CN CN201680041800.5A patent/CN107848991B/zh active Active
- 2016-06-10 AU AU2016275125A patent/AU2016275125A1/en not_active Abandoned
- 2016-06-10 SG SG10201911442XA patent/SG10201911442XA/en unknown
- 2016-06-10 WO PCT/US2016/037067 patent/WO2016201356A1/en not_active Ceased
- 2016-06-10 ES ES16808465T patent/ES2896674T3/es active Active
- 2016-06-10 US US15/735,560 patent/US10723726B2/en active Active
- 2016-06-10 JP JP2018516398A patent/JP2018521121A/ja active Pending
- 2016-06-10 CA CA2988584A patent/CA2988584C/en active Active
-
2017
- 2017-12-11 IL IL256237A patent/IL256237B/en unknown
-
2019
- 2019-11-05 US US16/675,097 patent/US11111239B2/en active Active
-
2020
- 2020-11-16 AU AU2020270457A patent/AU2020270457B2/en active Active
-
2022
- 2022-11-01 US US17/978,848 patent/US12227497B2/en active Active
-
2025
- 2025-01-09 US US19/015,307 patent/US20250353840A1/en active Pending